vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and BOSTON BEER CO INC (SAM). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $461.6M, roughly 1.5× BOSTON BEER CO INC). On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -4.1%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs -10.7%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
The Boston Beer Company is an American brewery founded in 1984 by James "Jim" Koch and Rhonda Kallman. Boston Beer Company's first brand of beer was named Samuel Adams after Founding Father Samuel Adams, an American revolutionary patriot. Since its founding, Boston Beer has started several other brands, and in 2019 completed a merger with Dogfish Head Brewery.
MEDP vs SAM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $461.6M |
| Net Profit | $135.1M | — |
| Gross Margin | — | 46.4% |
| Operating Margin | 21.6% | 12.4% |
| Net Margin | 19.1% | — |
| Revenue YoY | 32.0% | -4.1% |
| Net Profit YoY | 15.5% | — |
| EPS (diluted) | $4.65 | $2.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $461.6M | ||
| Q4 25 | $708.5M | $385.7M | ||
| Q3 25 | $659.9M | $537.5M | ||
| Q2 25 | $603.3M | $587.9M | ||
| Q1 25 | $558.6M | $453.9M | ||
| Q4 24 | $536.6M | $402.3M | ||
| Q3 24 | $533.3M | $605.5M | ||
| Q2 24 | $528.1M | $579.1M |
| Q1 26 | — | — | ||
| Q4 25 | $135.1M | $-22.5M | ||
| Q3 25 | $111.1M | $46.2M | ||
| Q2 25 | $90.3M | $60.4M | ||
| Q1 25 | $114.6M | $24.4M | ||
| Q4 24 | $117.0M | $-38.8M | ||
| Q3 24 | $96.4M | $33.5M | ||
| Q2 24 | $88.4M | $52.3M |
| Q1 26 | — | 46.4% | ||
| Q4 25 | — | 43.5% | ||
| Q3 25 | — | 50.8% | ||
| Q2 25 | — | 49.8% | ||
| Q1 25 | — | 48.3% | ||
| Q4 24 | — | 39.9% | ||
| Q3 24 | — | 46.3% | ||
| Q2 24 | — | 46.0% |
| Q1 26 | — | 12.4% | ||
| Q4 25 | 21.6% | -8.6% | ||
| Q3 25 | 21.5% | 11.5% | ||
| Q2 25 | 20.9% | 14.0% | ||
| Q1 25 | 20.3% | 7.4% | ||
| Q4 24 | 23.4% | -13.9% | ||
| Q3 24 | 21.1% | 7.6% | ||
| Q2 24 | 19.9% | 12.2% |
| Q1 26 | — | — | ||
| Q4 25 | 19.1% | -5.8% | ||
| Q3 25 | 16.8% | 8.6% | ||
| Q2 25 | 15.0% | 10.3% | ||
| Q1 25 | 20.5% | 5.4% | ||
| Q4 24 | 21.8% | -9.6% | ||
| Q3 24 | 18.1% | 5.5% | ||
| Q2 24 | 16.7% | 9.0% |
| Q1 26 | — | $2.16 | ||
| Q4 25 | $4.65 | $-1.97 | ||
| Q3 25 | $3.86 | $4.25 | ||
| Q2 25 | $3.10 | $5.45 | ||
| Q1 25 | $3.67 | $2.16 | ||
| Q4 24 | $3.67 | $-3.23 | ||
| Q3 24 | $3.01 | $2.86 | ||
| Q2 24 | $2.75 | $4.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $164.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $459.1M | $682.6M |
| Total Assets | $2.0B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $164.1M | ||
| Q4 25 | $497.0M | $223.4M | ||
| Q3 25 | $285.4M | $250.5M | ||
| Q2 25 | $46.3M | $212.4M | ||
| Q1 25 | $441.4M | $152.5M | ||
| Q4 24 | $669.4M | $211.8M | ||
| Q3 24 | $656.9M | $255.6M | ||
| Q2 24 | $510.9M | $219.3M |
| Q1 26 | — | $682.6M | ||
| Q4 25 | $459.1M | $846.3M | ||
| Q3 25 | $293.6M | $911.0M | ||
| Q2 25 | $172.4M | $912.3M | ||
| Q1 25 | $593.6M | $897.0M | ||
| Q4 24 | $825.5M | $916.2M | ||
| Q3 24 | $881.4M | $1.0B | ||
| Q2 24 | $763.6M | $1.0B |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.0B | $1.2B | ||
| Q3 25 | $1.8B | $1.2B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.9B | $1.2B | ||
| Q4 24 | $2.1B | $1.3B | ||
| Q3 24 | $2.1B | $1.4B | ||
| Q2 24 | $1.9B | $1.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | — |
| Free Cash FlowOCF − Capex | $188.1M | — |
| FCF MarginFCF / Revenue | 26.6% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | 1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $192.7M | $39.9M | ||
| Q3 25 | $246.2M | $101.8M | ||
| Q2 25 | $148.5M | $126.5M | ||
| Q1 25 | $125.8M | $1.9M | ||
| Q4 24 | $190.7M | $41.9M | ||
| Q3 24 | $149.1M | $115.9M | ||
| Q2 24 | $116.4M | $96.0M |
| Q1 26 | — | — | ||
| Q4 25 | $188.1M | $22.1M | ||
| Q3 25 | $235.5M | $89.2M | ||
| Q2 25 | $142.4M | $112.2M | ||
| Q1 25 | $115.8M | $-8.0M | ||
| Q4 24 | $183.0M | $18.4M | ||
| Q3 24 | $138.5M | $99.2M | ||
| Q2 24 | $103.5M | $75.6M |
| Q1 26 | — | — | ||
| Q4 25 | 26.6% | 5.7% | ||
| Q3 25 | 35.7% | 16.6% | ||
| Q2 25 | 23.6% | 19.1% | ||
| Q1 25 | 20.7% | -1.8% | ||
| Q4 24 | 34.1% | 4.6% | ||
| Q3 24 | 26.0% | 16.4% | ||
| Q2 24 | 19.6% | 13.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | 4.6% | ||
| Q3 25 | 1.6% | 2.3% | ||
| Q2 25 | 1.0% | 2.4% | ||
| Q1 25 | 1.8% | 2.2% | ||
| Q4 24 | 1.4% | 5.8% | ||
| Q3 24 | 2.0% | 2.8% | ||
| Q2 24 | 2.4% | 3.5% |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | — | ||
| Q3 25 | 2.22× | 2.21× | ||
| Q2 25 | 1.65× | 2.09× | ||
| Q1 25 | 1.10× | 0.08× | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.55× | 3.46× | ||
| Q2 24 | 1.32× | 1.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
SAM
Segment breakdown not available.
